Initial Beneficial Ownership · 3
AEON Biopharma, Inc.
AEONNYSE_AMERICANEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
form3.xml
Filing details
- Report period
- 2026-08-19
- Issuer
- AEON Biopharma, Inc.
- Issuer CIK
- 0001837607
- Trading symbol
- AEON
Reporting owner 1
- Name
- LYNCH TIMOTHY P
- Reporting owner CIK
- 0001270925
- Relationship
- 10% owner
- Address
- 70 SW CENTURY DR., STE. 100, BEND, OR, 97702
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Class A Common Stock | 5,350,000 | D |
Table key
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership |
|---|---|---|---|---|---|---|
| Pre-Funded Warrants | 0.0001 | [F1] | [F1] | Class A Common Stock | 1,000,000[F2] | D |
| Warrants | 0.3221 | 2026-07-15 | [F3] | Class A Common Stock[F4] | 3,000,000[F2] | D |
| Warrants | 0.3704 | 2026-07-15 | [F5] | Class A Common Stock[F6] | 3,000,000[F2] | D |
Table key
- D
- Direct
Footnotes
- F2
- The reporting person (together with his affiliates) may not exercise any portion of these warrant to the extent that, after giving effect to such exercise, the reporting person would beneficially own more than 4.99% of the outstanding shares of Class A Common Stock immediately after exercise. The beneficial ownership limitation may be increased or decreased at the reporting person's election to a percentage not in excess of 19.99%, upon at least 61 days' prior written notice to us, subject to the terms of the warrants.↩ 1↩ 2↩ 3
- F3
- These warrants will expire on the earlier of (i) the second anniversary of the date of issuance and (ii) the 45th day following the Issuer's public announcement that it has received Type 2B meeting minutes from the FDA regarding certain matters.↩ 1
- F4
- At the option of the reporting person, each of these warrants may be exercised for either one share of Class A Common Stock or one pre-funded warrant to acquire Class A Common Stock.↩ 1
- F5
- These warrants will expire on the earlier of (i) the fifth anniversary of the date of issuance and (ii) 45 days following the Issuer's public announcement that the Issuer has initiated a Phase 3 clinical equivalence trial of ABP-450 as a biosimilar to BOTOX.↩ 1
- F6
- At the option of the reporting person, each of these warrants may be exercised for either one share of Class A Common Stock or one pre-funded warrant to acquire Class A Common Stock.↩ 1
Signature 1
- Signed
- /s/ Timothy P. Lynch
- Date
- 2026-08-21
Company context
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.